全文获取类型
收费全文 | 19685篇 |
免费 | 1400篇 |
国内免费 | 96篇 |
专业分类
耳鼻咽喉 | 192篇 |
儿科学 | 533篇 |
妇产科学 | 402篇 |
基础医学 | 2192篇 |
口腔科学 | 357篇 |
临床医学 | 1724篇 |
内科学 | 4168篇 |
皮肤病学 | 329篇 |
神经病学 | 1059篇 |
特种医学 | 656篇 |
外科学 | 3459篇 |
综合类 | 730篇 |
现状与发展 | 30篇 |
一般理论 | 17篇 |
预防医学 | 1470篇 |
眼科学 | 521篇 |
药学 | 1861篇 |
中国医学 | 221篇 |
肿瘤学 | 1260篇 |
出版年
2023年 | 348篇 |
2022年 | 523篇 |
2021年 | 665篇 |
2020年 | 475篇 |
2019年 | 548篇 |
2018年 | 685篇 |
2017年 | 487篇 |
2016年 | 398篇 |
2015年 | 554篇 |
2014年 | 770篇 |
2013年 | 920篇 |
2012年 | 1307篇 |
2011年 | 1290篇 |
2010年 | 801篇 |
2009年 | 644篇 |
2008年 | 1015篇 |
2007年 | 1029篇 |
2006年 | 928篇 |
2005年 | 856篇 |
2004年 | 777篇 |
2003年 | 702篇 |
2002年 | 594篇 |
2001年 | 552篇 |
2000年 | 498篇 |
1999年 | 414篇 |
1998年 | 178篇 |
1997年 | 162篇 |
1996年 | 147篇 |
1995年 | 150篇 |
1994年 | 89篇 |
1993年 | 109篇 |
1992年 | 209篇 |
1991年 | 193篇 |
1990年 | 171篇 |
1989年 | 192篇 |
1988年 | 154篇 |
1987年 | 166篇 |
1986年 | 127篇 |
1985年 | 145篇 |
1984年 | 114篇 |
1983年 | 89篇 |
1982年 | 67篇 |
1981年 | 70篇 |
1979年 | 98篇 |
1978年 | 69篇 |
1977年 | 69篇 |
1976年 | 61篇 |
1975年 | 70篇 |
1974年 | 54篇 |
1973年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
Gnanapragasam VJ Darby S Khan MM Lock WG Robson CN Leung HY 《The Journal of pathology》2005,206(2):205-213
Gonadotropin-releasing hormone analogue (GnRHa) therapy is an established method of androgen withdrawal in the treatment of prostate cancer. The present study investigated if the expression of prostate GnRH receptors (GnRHRs) might influence the response to GnRHa. GnRHR protein expression was first studied in a panel of prostate cancer cell lines. In androgen-dependent cells, GnRHR expression was unchanged following acute or chronic androgen withdrawal. In these cells, GnRHa significantly inhibited androgen-induced cell proliferation (p = 0.01). In contrast, GnRHa was unable to further suppress basal levels of cell proliferation induced by androgen withdrawal. In androgen-independent prostate cancer cells, variable levels of GnRHR expression were observed. In these cells, GnRHa treatment blocked cell proliferation (p = 0.001) and invasion (up to 70%) induced by fibroblast growth factor stimulation. Crucially, this effect was only evident in cells that expressed high levels of the GnRHR. GnRHa treatment also significantly inhibited the ability of these cells to recover from a cytotoxic insult (50% inhibition). The clinical significance of prostate GnRHR was tested by immunohistochemistry in a preliminary cohort of patients treated with GnRHa or surgical castration. There was no association between GnRHR expression and pathological grade, clinical stage, time to PSA nadir (p = 0.82) (n = 35) or progression to hormone refractory disease (p = 0.22) (n = 21), irrespective of the treatment method. GnRHa therapy in the presence of high GnRHR expression however, was found to be associated with longer disease-specific survival (mean survival 85 months, p = 0.002). In contrast, high GnRHR expression was not associated with survival among surgically castrated patients (mean survival 50 months, p = 0.7). Taken together, these data support the notion of a functional interaction between GnRHa and the GnRHR, which results in an anti-tumourigenic effect on prostate cancer cells. Findings from this report have direct implications for the use of GnRHR as a novel therapeutic target in hormone refractory prostate cancer. 相似文献
122.
123.
Priest JW Li A Khan M Arrowood MJ Lammie PJ Ong CS Roberts JM Isaac-Renton J 《Clinical and diagnostic laboratory immunology》2001,8(2):415-423
Cryptosporidium parvum is a protozoan parasite that causes diarrheal illness in a wide range of mammalian hosts, including humans. Characteristic serum immunoglobulin G (IgG) antibody responses to antigens in the 27- and 17-kDa size ranges have been shown to develop after infection, and several enzyme-linked immunosorbent assay (ELISA) and Western blot assay formats have been used to measure these IgG levels in human serum. Using a collection of serial samples from laboratory-confirmed cryptosporidiosis patients, we compared the results obtained by using two new ELISAs with those obtained with two different Western blot assays. When assayed with the large-format Western blot, 97% of the 67 patients had a demonstrable antibody response on at least one occasion. The Cp23 ELISA correctly identified 93% of the samples that had a 27-kDa response by Western blot and 100% of the negative samples. The Triton antigen ELISA detected 77% of the samples that had a 17-kDa response by Western blot and 88% of the negative samples. The sensitivity of the Triton antigen assay was higher for samples collected between 16 and 92 days after the onset of symptoms (96%). The minigel-format Western blot did not compare favorably with the large-format blot for the detection of antibodies to the 27-kDa antigen (71% sensitivity). A half-life of about 12 weeks was estimated for antibodies to both the 27- and 17-kDa antigens. We believe the Cp23 and Triton antigen ELISAs will be useful in epidemiologic studies of the prevalence of Cryptosporidium infection in the population. 相似文献
124.
Comparative mutagenic and genotoxic effects of three antimalarial drugs, chloroquine, primaquine and amodiaquine 总被引:1,自引:0,他引:1
Chatterjee Taraknath; Muhkopadhyay Amitabha; Khan Kalim A.; K.Giri Ashok 《Mutagenesis》1998,13(6):619-624
Comparative mutagenic and genotoxic effects of three antimalarialdrugs, chloroquine, primaquine and amodiaquine, were assessedin the Ames mutagenicity assay (in strains TA97a, TA100, TA102and TA104) and in vivo sister chromatid exchange (SCE) and chromosomeaberration (CA) assays in bone marrow cells of mice. These arethe most commonly used antimalarial drugs available at presentthroughout the world. The results of the bacterial mutagenicityassays showed a very weak mutagenic effect of all three drugsin Salmonella strains TA97a and TA100 both with and withoutS9 mix and in TA104 only with S9 mix. The results of the invivo SCE and CA assays indicate that these three drugs are genotoxicin bone marrow cells of mice.
3To whom correspodence should be addressed. Tel: +91 33 473 3491; Fax: +91 33 473 5197; Email: iichbio{at}giascl01.vsnl.net.in 相似文献
125.
The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis 总被引:5,自引:0,他引:5
Maheshwar MM; Cheadle JP; Jones AC; Myring J; Fryer AE; Harris PC; Sampson JR 《Human molecular genetics》1997,6(11):1991-1996
Tuberous sclerosis is an autosomal dominant trait in which the
dysregulation of cellular proliferation and differentiation results in the
development of hamartomatous growths in many organs. The TSC2 gene is one
of two genes determining tuberous sclerosis. Inactivating germline
mutations of TSC2 in patients with tuberous sclerosis and somatic loss of
heterozygosity at the TSC2 locus in the associated hamartomas indicate that
TSC2 functions as a tumour suppressor gene and that loss of function is
critical to expression of the tuberous sclerosis phenotype. The TSC2
product, tuberin, has a region of homology with the GTPase activating
protein rap1GAP and stimulates the GTPase activity of rap1a and rab5a in
vitro. Here we show that the region of homology between tuberin and human
rap1GAP and the murine GAP mSpa1 is more extensive than previously reported
and spans approximately 160 amino acid residues encoded within exons 34-38
of the TSC2 gene. Single strand conformation polymorphism analysis of these
exons in 173 unrelated patients with tuberous sclerosis and direct
sequencing of variant conformers together with study of additional family
members enabled characterisation of disease associated mutations in 14
cases. Missense mutations, which occurred in exons 36, 37 and 38 were
identified in eight cases, four of whom shared the same recurrent change
P1675L. Each of the five different missense mutations identified was shown
to occur de novo in at least one sporadic case of tuberous sclerosis. The
high proportion of missense mutations detected in the region of the TSC2
gene encoding the GAP-related domain supports its key role in the
regulation of cellular growth.
相似文献
126.
Morse MA Garst J Osada T Khan S Hobeika A Clay TM Valente N Shreeniwas R Sutton MA Delcayre A Hsu DH Le Pecq JB Lyerly HK 《Journal of translational medicine》2005,3(1):9-8
BACKGROUND: There is a continued need to develop more effective cancer immunotherapy strategies. Exosomes, cell-derived lipid vesicles that express high levels of a narrow spectrum of cell proteins represent a novel platform for delivering high levels of antigen in conjunction with costimulatory molecules. We performed this study to test the safety, feasibility and efficacy of autologous dendritic cell (DC)-derived exosomes (DEX) loaded with the MAGE tumor antigens in patients with non-small cell lung cancer (NSCLC). METHODS: This Phase I study enrolled HLA A2+ patients with pre-treated Stage IIIb (N = 4) and IV (N = 9) NSCLC with tumor expression of MAGE-A3 or A4. Patients underwent leukapheresis to generate DC from which DEX were produced and loaded with MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides. Patients received 4 doses of DEX at weekly intervals. RESULTS: Thirteen patients were enrolled and 9 completed therapy. Three formulations of DEX were evaluated; all were well tolerated with only grade 1-2 adverse events related to the use of DEX (injection site reactions (N = 8), flu like illness (N = 1), and peripheral arm pain (N = 1)). The time from the first dose of DEX until disease progression was 30 to 429+ days. Three patients had disease progression before the first DEX dose. Survival of patients after the first DEX dose was 52-665+ days. DTH reactivity against MAGE peptides was detected in 3/9 patients. Immune responses were detected in patients as follows: MAGE-specific T cell responses in 1/3, increased NK lytic activity in 2/4. CONCLUSION: Production of the DEX vaccine was feasible and DEX therapy was well tolerated in patients with advanced NSCLC. Some patients experienced long term stability of disease and activation of immune effectors. 相似文献
127.
128.
Summary A new species, B. similis, is described from male and female specimens collected from soil around roots of Plumeria acutifolia
Poir from North India. It is distinguished by a short and robust body, a broad lateral field, a more posteriorly located vulva in female and the position of phasmid and the posterior extension of lateral field in male.With 8 Figures in the Text 相似文献
129.
目的 探讨可溶性 HLA-G1(sHLA-G1)对人 NK-92 细胞杀伤活性的抑制与细胞表面免疫球蛋白样转录分子 2(ILT2)和杀伤细胞免疫球蛋白样受体 2DL4(KIR2DL4)受体的关系。 方法 ①通过原核表达技术获得 sHLA-G1 重组蛋白(重组蛋白),并采用蛋白质印迹法进行鉴定。②取 NK-92 细胞,加入终浓度 20 μg/ml 的重组蛋白分别培养 10、30 min,再分别加入抗 HLA-G1/G5、抗ILT2 和抗 KIR2DL4 抗体,采用流式细胞术检测各组 NK-92 细胞表面 sHLA-G1 和 ILT2、KIR2DL4 受体表达阳性率;以 NK-92 细胞单独培养作为对照组。③以人白血病 K562 细胞为靶细胞,以经不同方式处理的 NK-92 细胞为效应细胞,效靶比为5:1,共同培养 2 h,采用流式细胞术检测 NK-92 细胞对 K562 细胞的杀伤率。NK-92 细胞处理方式为单纯重组蛋白处理(分别加入终浓度为 0、10、20 μg/ml 的重组蛋白培养 30 min)和表面受体封闭 + 重组蛋白处理(分别加入抗 ILT2、抗 KIR2DL4、抗 LT2 + 抗 KIR2DL4 抗体培养 30 min,再分别加入终浓度为 0、10、20 μg/ml 的重组蛋白培养 30 min)。 结果 ①蛋白质印迹分析表明所获重组蛋白为带有组氨酸标签的特异蛋白。②NK-92 细胞与 20 μg/ml 重组蛋白共培养 30 min 后,sHLA-G1 表达阳性率明显高于而 ILT2、KIR2DL4 受体表达阳性率均明显低于对照组(均 P < 0.05)。③以终浓度 0、10、20 μg/ml 的重组蛋白处理的 NK-92 细胞对 K562 细胞的杀伤率分别为 39.79% ± 2.00%、27.79% ± 0.75%、21.36% ± 0.67%(两两比较,均 P < 0.01);单独封闭 ILT2 受体,杀伤率分别为 23.09% ± 1.63%、21.13% ± 0.38%、18.42% ± 0.47%(两两比较,均 P < 0.01);单独封闭 KIR2DL4 受体,杀伤率分别为 30.74% ± 0.44%、26.03% ± 0.38%、21.15% ± 0.35%(两两比较,均 P < 0.01)。 结论 sHLA-G1 通过与 NK-92 细胞表面 ILT2 和 KIR2DL4 受体直接结合而抑制 NK-92 细胞的杀伤活性。 相似文献
130.
Development of a blocking enzyme-linked immunosorbent assay for the detection of avian polyomavirus-specific antibodies 总被引:5,自引:0,他引:5
Khan MS Johne R Beck I Pawlita M Kaleta EF Müller H 《Journal of virological methods》2000,89(1-2):39-48
Avian polyomavirus, described originally as budgerigar fledgling disease virus, has been associated with devastating contagious disease outbreaks in budgerigar aviaries. At present, this virus affects a wide range of psittacine and non-psittacine birds worldwide, and the serum neutralisation test is used for the serodiagnosis of avian polyomavirus infections. A blocking enzyme-linked immunosorbent assay was developed for the screening of large numbers of sera collected from various avian species. The assay employs a monoclonal antibody directed against the major structural protein VP1 as a blocking antibody in a sandwich blocking procedure. Either purified avian polyomavirus particles or avian polyomavirus VP1 expressed in recombinant baculovirus-infected Sf9 cells were used as antigen. The specificity of the blocking enzyme-linked immunosorbent assay was evaluated by testing sera directed against mammalian polyomaviruses. Using sera obtained from chicken infected experimentally with avian polyomavirus and a collection of psittacine field-origin sera, a good correlation was observed between the results of the blocking enzyme-linked immunosorbent assay and the serum neutralisation test. However, the blocking enzyme-linked immunosorbent assay is more rapid and more economic. Both, avian polyomavirus particles and VP1 produced by recombinant DNA technology proved to be suitable antigens. 相似文献